KIAA0284 Activators
Signal transducing ubiquitin ligases empower KIAA0284 duties, interacting to precisely control protein quality. Agents perturbing UPR/IRE1-XBP1 arms optimize KIAA0284 engagement of this adaptive response machinery against stress. Transport blockers activate compensatory KIAA0284 redistribution of cargoes.
Post-translational mechanisms further modulate KIAA0284 functions. Enhanced homovanillic acid-mediated ubiquitylation potentiates substrate catabolism.Calcium/calmodulin influence also shapes KIAA0284 signaling. Proteotoxins stimulating release optimize accessibility of targets and ligase activity potentiation.Homocysteine or hyperglycemia compromise interactions optimized by KIAA0284. Homovanillic acid boosts KIAA0284 E3 ligase capacities while DUB inhibitor MG-115 provides substrates offset through enhanced ubiquitylation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine inhibits kinases to disrupt protein regulation. KIAA0284 controls ubiquitylationdependent protein turnover, so staurosporine enhances substrate access. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A alters Golgi trafficking. KIAA0284 coordinates with intra-Golgi transport for selective proteolysis of cargoes. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 inhibits proteasomal function. KIAA0284 enhances compensatory polyubiquitylation and downregulation of substrates at impaired processing points. | ||||||
Arsenic(III) oxide | 1327-53-3 | sc-210837 sc-210837A | 250 g 1 kg | $89.00 $228.00 | ||
Arsenic trioxide generates oxidative stress. KIAA0284 mitigates damage through optimized degradation of oxidized protein species. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $176.00 $426.00 | 43 | |
Doxorubicin triggers DNA damage and redox imbalance. KIAA0284 resolves such genotoxin-derived proteome imbalances via E3 ligase regulation. | ||||||
L-Methionine | 63-68-3 | sc-394076 sc-394076A sc-394076B sc-394076C sc-394076D sc-394076E | 25 g 100 g 250 g 1 kg 5 kg 10 kg | $34.00 $37.00 $57.00 $151.00 $577.00 $1103.00 | ||
Hyperhomocysteinemia induces ER dysfunction. KIAA0284 works to relieve disulfide rearrangement-derived lesions. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin blocks N-glycosylation eliciting UPR. KIAA0284 acts downstream of IRE1-XBP1 signaling optimization. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
2-Deoxyglucose inhibits glycolysis triggering proteotoxicity. KIAA0284 counteracts accumulated substrate lesions. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib inhibits proteasomal function inducing misfolding. KIAA0284 rescues homeostasis through augmented E3 ligase catalyzedproteinprocessing. | ||||||
MG-115 | 133407-86-0 | sc-221940 sc-221940A | 1 mg 5 mg | $89.00 $224.00 | 3 | |
MG-115 inhibits deubiquitylating enzymes to instigate substrate accrual. KIAA0284 offsets imbalance via optimized polyubiquitylation. | ||||||